Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

Inclusion Criteria: * Have no cognitive impairment that may prevent patient from completing questionnaires, as assessed by examining physicians during screening * Diagnosis of early (\<1 year since onset) RRMS, or a first clinical episode suggestive of demyelinating disease (not explained by other conditions) within the last 90 days prior to screening * Presence of at least 2 typical MS lesions by brain MRI * Kurtzke Expanded Disability Status Scale (EDSS) score of 0 - 4.0 * Willing to enroll into the MS Pathways support program and by doing so agree to be trained, and have follow-up phone calls, by a B.E.T.A. nurse Exclusion Criteria: * Any disease other than multiple sclerosis that would better explain the patient's neurological signs and symptoms * Complete transverse myelitis or simultaneous onset of optic neuritis * Diagnosis of Primary progressive MS, secondary Progressive MS, relapsing progressive MS or a diagnosis of relapsing remitting MS for greater than 12 months * Clinically significant heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled heart failure * History of severe, uncontrolled, or untreated depression, attempted suicide or suicidal ideation * Uncontrolled seizure disorder * History or hypergammaglobulinemia * Known hypersensitivity to IFNB-1b or other human proteins including albumin * Known allergy to Gadolinium-DTPA documented prior to study entry * Known general hypersensitivity to all analgesic / antiinflammatory agents (NSAIDs) * Participation in any MS clinical study within the past six months * Pre-treatment with any of the following substances prior to study enrollment within said time period: * At any time: any IFN, glatiramer acetate (Copaxone), total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment (i.e. anti-CD4, anti-CD52 (alemtuzumab), anti-VLA4 (natalizumab), mitoxantrone, cyclophosphamide, azathioprine, IVIG, cyclosporine A, methotrexate, or any other immunomodulating or immunosuppressive agent including other recombinant or non-recombinant cytokines * 3 months prior to study entry: any other treatment known to be used for putative or experimental MS treatment. Any presumed immunomodulating agent (e.g. statins) not described in this protocol * History of alcohol or substance abuse (within the past 5 years) * Inability or unwillingness to administer subcutaneous injections either by self or by caregiver * Clinically significant hepatic, renal, or bone marrow dysfunction as defined by any of the following laboratory evaluations: * Hepatic dysfunction: AST (SGOT) \> 3x the upper limit of normal or total bilirubin \> 2x upper limit of normal * Renal dysfunction: creatinine \> 1.8 mg/dl * Bone marrow dysfunction: Hb \< 8.5 g/dl, WBC \< 2.5x10\^9/L, or platelet count \< 125x10\^9/L * Patients participating in the exploratory substudy should be excluded if they meet any of the following: * Known history of chronic glaucoma, ocular hypertension, ischemic optic neuropathy, temporal arteritis, pseudopapilledema, retinitis pigmentosa, traumatic optic neuropathy, toxic optic neuropathy, pernicious anemia, or Leber's hereditary optic neuritis